Cardio drug maker Portola Pharmaceuticals takes $60M extension
San Francisco-based drug company Portola Pharmaceuticals has taken a $60 million extension to its third round of funding to see it through Phase II trials for betrixaban, a drug intended to prevent blood clots.
The company is also working on an antiplatelet agent called PRT060128. If… Continue Reading
Life sciences briefing: Tuesday, Jan. 8, 2008
TODAY’S HEADLINES:
CyberHeart pumps in $9M for cardiac-arrhythmia treatment (release)
Incubator ForSight launches third device company with $6M funding (release)
Primera Biosystems raises $21M for molecular diagnostics (release)
Biogen Idec, PDL BioPharma take stakes in Ophthotech (release)
Technitrol acquires medical-device component maker Sonion for $385M (release)
DLJ Merchant Banking takes control… Continue Reading
Life sciences briefing: Thursday, Dec. 13, 2007
TODAY’S HEADLINES:
Fovea Pharma sees €30M for eye drugs (release)
Ascendis Pharma raises €18M for time-release drugs (PDF release)
Arcion draws $9M for topical pain drugs (VentureWire, sub req’d)
Saladax Biomedical raises $8M for chemotherapy diagnostics (VW)
MedAssets prices IPO at top of range, raises up to $221M (IPO Home)
Pequot… Continue Reading
Cardiovascular biotech Portola Pharmaceuticals raises $70M, eyes IPO
Portola Pharmaceuticals, a South San Francisco, Calif., biotech aiming to develop treatments for blood clots and other heart-related problems, raised $70 million in a third round of financing dominated by late-stage and public-market investors.
Among new investors in the round were Brookside Capital; AllianceBernstein; Teachers’ Private… Continue Reading
Portola Pharma gets $20M debt financing
Portola Pharmaceuticals, a South San Francisco biotech company developing cardiovascular and vascular disease therapies, has raised $20 million in debt financing from Hercules Technology Growth Capital.
Portola is already backed by venture firms Abingworth, Alta Partners, ATV, Frazier Healthcare Ventures, MPM Capital, Prospect Ventures and Sutter… Continue Reading